Drug Profile

Epoetin alfa biosimilar - PanGen Biotech

Alternative Names: Erysaa; Panpotin; PDA 10

Latest Information Update: 15 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PanGen Biotech
Developer Duopharma; PanGen Biotech
Class Antianaemics; Recombinant erythropoietins
Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Anaemia

Most Recent Events

15 Dec 2025 Launched for Anaemia in Turkey, Philippines, Saudi Arabia, South Korea (IV), prior to December 2025 (PanGen Biotech pipeline, December 2025)
24 Sep 2024 Registered for Anaemia in Thailand (IV) (PanGen Biotech pipeline, December 2025)
01 Jan 2023 Registered for Anaemia in Saudi Arabia (IV) (PanGen Biotech pipeline, December 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com